22:01 , Nov 16, 2017 |  BC Extra  |  Financial News

Protein misfolding play Orphazyme prices IPO

Protein misfolding company Orphazyme A/S (CSE:ORPHA TEMP) was unchanged on Thursday after it debuted on NASDAQ Copenhagen, raising DKK 600 million ($94.1 million) in an IPO through the sale of 7.5 million shares at DKK...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Company News

Topotarget cancer news

TopoTarget reduced headcount by eight (17%) to 40, with the cuts including CFO Tim Corcoran, COO Steven Butcher and members of the company's research and preclinical development organization. The company expects the reductions to generate...
07:00 , Aug 24, 2009 |  BioCentury  |  Finance

Ebb & Flow

Having granted U.S. marketing rights to Intermezzo zolpidem to Purdue Pharma L.P. earlier this month, Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) last week said it would cut the staff made superfluous by the deal. It will trim...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Financial News

TopoTarget completes rights offering

TopoTarget A/S (CSE:TOPO), Copenhagen, Denmark   Business: Cancer   Date completed: 6/24/09   Type: Rights offering   Raised: DKK16.7 million ($3.1 million)   Shares: 8.3 million   Price: DKK2   Shares after offering: 74.6 million...
02:04 , Aug 20, 2008 |  BC Extra  |  Financial News

F2G raises L6.3 million

F2G (Manchester, U.K.) raised L6.3 million ($11.8 million) in the second and final close of a series B round, bringing the total raised in the round to L11.3 million ($20.5 million). Existing investor BankInvest led...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
08:00 , Jan 7, 2008 |  BioCentury  |  Strategy

Selling out to reach the finish line

Investors in Hormos Medical Corp. decided in 2005 that they were better off putting the Finnish company's compounds in the hands of an acquirer with clinical development skills than getting more funding at a reduced...
01:33 , Dec 19, 2007 |  BC Extra  |  Financial News

Santaris raises EUR 20.4 million

Santaris (Horsholm, Denmark) raised EUR 20.4 million ($29.4 million) in a series C round. New investor Gilde joined existing investors BankInvest; Novo A/S; LD Pension Fund; Forbion Capital Partners; Global Life Science Venture; Sunstone Capital;...
07:00 , Aug 13, 2007 |  BC Week In Review  |  Company News

Nereus board of directors update

Nereus Pharmaceuticals Inc. , San Diego, Calif.   Business: Cancer, Infectious, Inflammation   Appointed: Jesper Zeuthen, managing director of BankInvest Biomedical Venture; and Erich Platzer, investment advisor for HBM Partners AG  ...
23:52 , Aug 9, 2007 |  BC Extra  |  Financial News

Nereus raises $45 million

Nereus (San Diego, Calif.) raised $45 million in a series D-2 round led by new investor BankInvest Biomedical Venture. Other new investors Roche Venture Fund; Astellas Venture Management; Boston Life Science Venture Corp.; Taiwan Global...